Abstract OT1-01-04: A phase 2, open-label study of imprime PGG (Imprime), a novel beta glucan, with pembrolizumab (Pembro) in chemotherapy-resistant metastatic triple negative breast cancer (TNBC)

SJ O'Day; AT Stopeck; RD Huhn; MA Gargano; R Prathikanti; B Ma; PM Mattson; JR Lowe; N Bose; KE Ertelt; NC Ottoson; MT Uhlik; JR Graff; MJ Chisamore

doi:10.1158/1538-7445.SABCS17-OT1-01-04

Ongoing Clinical Trials

Abstract OT1-01-04: A phase 2, open-label study of imprime PGG (Imprime), a novel beta glucan, with pembrolizumab (Pembro) in chemotherapy-resistant metastatic triple negative breast cancer (TNBC)

SJ O'Day, AT Stopeck, RD Huhn, MA Gargano, R Prathikanti, B Ma, PM Mattson, JR Lowe, N Bose, KE Ertelt, NC Ottoson, MT Uhlik, JR Graff and MJ Chisamore

SJ O'Day

John Wayne Cancer Institute, Santa Monica, CA; Stony Brook University, Stony Brook, NY; Biothera Pharmaceuticals, Inc., Eagan, MN; Merck & Co., Inc., Kenilworth, NJ

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

AT Stopeck

John Wayne Cancer Institute, Santa Monica, CA; Stony Brook University, Stony Brook, NY; Biothera Pharmaceuticals, Inc., Eagan, MN; Merck & Co., Inc., Kenilworth, NJ

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

RD Huhn

John Wayne Cancer Institute, Santa Monica, CA; Stony Brook University, Stony Brook, NY; Biothera Pharmaceuticals, Inc., Eagan, MN; Merck & Co., Inc., Kenilworth, NJ

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

MA Gargano

John Wayne Cancer Institute, Santa Monica, CA; Stony Brook University, Stony Brook, NY; Biothera Pharmaceuticals, Inc., Eagan, MN; Merck & Co., Inc., Kenilworth, NJ

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

R Prathikanti

John Wayne Cancer Institute, Santa Monica, CA; Stony Brook University, Stony Brook, NY; Biothera Pharmaceuticals, Inc., Eagan, MN; Merck & Co., Inc., Kenilworth, NJ

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

B Ma

John Wayne Cancer Institute, Santa Monica, CA; Stony Brook University, Stony Brook, NY; Biothera Pharmaceuticals, Inc., Eagan, MN; Merck & Co., Inc., Kenilworth, NJ

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

PM Mattson

John Wayne Cancer Institute, Santa Monica, CA; Stony Brook University, Stony Brook, NY; Biothera Pharmaceuticals, Inc., Eagan, MN; Merck & Co., Inc., Kenilworth, NJ

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

JR Lowe

John Wayne Cancer Institute, Santa Monica, CA; Stony Brook University, Stony Brook, NY; Biothera Pharmaceuticals, Inc., Eagan, MN; Merck & Co., Inc., Kenilworth, NJ

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

N Bose

John Wayne Cancer Institute, Santa Monica, CA; Stony Brook University, Stony Brook, NY; Biothera Pharmaceuticals, Inc., Eagan, MN; Merck & Co., Inc., Kenilworth, NJ

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

KE Ertelt

John Wayne Cancer Institute, Santa Monica, CA; Stony Brook University, Stony Brook, NY; Biothera Pharmaceuticals, Inc., Eagan, MN; Merck & Co., Inc., Kenilworth, NJ

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

NC Ottoson

John Wayne Cancer Institute, Santa Monica, CA; Stony Brook University, Stony Brook, NY; Biothera Pharmaceuticals, Inc., Eagan, MN; Merck & Co., Inc., Kenilworth, NJ

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

MT Uhlik

John Wayne Cancer Institute, Santa Monica, CA; Stony Brook University, Stony Brook, NY; Biothera Pharmaceuticals, Inc., Eagan, MN; Merck & Co., Inc., Kenilworth, NJ

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

JR Graff

John Wayne Cancer Institute, Santa Monica, CA; Stony Brook University, Stony Brook, NY; Biothera Pharmaceuticals, Inc., Eagan, MN; Merck & Co., Inc., Kenilworth, NJ

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

MJ Chisamore

John Wayne Cancer Institute, Santa Monica, CA; Stony Brook University, Stony Brook, NY; Biothera Pharmaceuticals, Inc., Eagan, MN; Merck & Co., Inc., Kenilworth, NJ

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

DOI: 10.1158/1538-7445.SABCS17-OT1-01-04 Published February 2018

Article
Info & Metrics

Online Impact

Statistics from Altmetric.com

ARTICLE USAGE

ARTICLE USAGE: February 2018 to February 2021

	Abstract	Full-text HTML	PDF
Total	626	0	0

Cited By

Article Information

Volume 78, Issue 4 Supplement, pp. OT1-01-04

DOI

https://doi.org/10.1158/1538-7445.SABCS17-OT1-01-04

Published By

American Association for Cancer Research

Print ISSN

0008-5472

Online ISSN

1538-7445

Author Information

SJ O'Day,
AT Stopeck,
RD Huhn,
MA Gargano,
R Prathikanti,
B Ma,
PM Mattson,
JR Lowe,
N Bose,
KE Ertelt,
NC Ottoson,
MT Uhlik,
JR Graff, and
MJ Chisamore

John Wayne Cancer Institute, Santa Monica, CA; Stony Brook University, Stony Brook, NY; Biothera Pharmaceuticals, Inc., Eagan, MN; Merck & Co., Inc., Kenilworth, NJ

February 2018
Volume 78, Issue 4 Supplement

Table of Contents

Search for this keyword

Article Alerts

User Name *

Password *

Email *

Email Article

Thank you for sharing this Cancer Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Your Email *

Your Name *

Send To *

Enter multiple addresses on separate lines or separate them with commas.

You are going to email the following Abstract OT1-01-04: A phase 2, open-label study of imprime PGG (Imprime), a novel beta glucan, with pembrolizumab (Pembro) in chemotherapy-resistant metastatic triple negative breast cancer (TNBC)

Message Subject (Your Name) has forwarded a page to you from Cancer Research

Message Body (Your Name) thought you would be interested in this article in Cancer Research.

Your Personal Message

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Citation Tools

Abstract OT1-01-04: A phase 2, open-label study of imprime PGG (Imprime), a novel beta glucan, with pembrolizumab (Pembro) in chemotherapy-resistant metastatic triple negative breast cancer (TNBC)

SJ O'Day, AT Stopeck, RD Huhn, MA Gargano, R Prathikanti, B Ma, PM Mattson, JR Lowe, N Bose, KE Ertelt, NC Ottoson, MT Uhlik, JR Graff and MJ Chisamore

Cancer Res February 15 2018 (78) (4 Supplement) OT1-01-04; DOI: 10.1158/1538-7445.SABCS17-OT1-01-04

Citation Manager Formats

BibTeX
Bookends
EasyBib
EndNote (tagged)
EndNote 8 (xml)
Medlars
Mendeley
Papers
RefWorks Tagged
Ref Manager
RIS
Zotero

Abstract OT1-01-04: A phase 2, open-label study of imprime PGG (Imprime), a novel beta glucan, with pembrolizumab (Pembro) in chemotherapy-resistant metastatic triple negative breast cancer (TNBC)

SJ O'Day, AT Stopeck, RD Huhn, MA Gargano, R Prathikanti, B Ma, PM Mattson, JR Lowe, N Bose, KE Ertelt, NC Ottoson, MT Uhlik, JR Graff and MJ Chisamore

Cancer Res February 15 2018 (78) (4 Supplement) OT1-01-04; DOI: 10.1158/1538-7445.SABCS17-OT1-01-04

Share This Article:

Tweet Widget
Facebook Like
Google Plus One

Jump to section

Article
Info & Metrics

Cited By...

Ongoing Clinical Trials

Abstract OT1-08-09: CONTESSA: A multinational, multicenter, randomized, phase 3 registration study of tesetaxel plus a reduced dose of capecitabine in patients with HER2-, hormone receptor + (HR+) metastatic breast cancer (MBC) who have previously received a taxane
Abstract OT1-01-06: A pilot study utilizing a HER2 directed dendritic cell vaccine during neoadjuvant therapy of HER2+ breast cancer
Abstract OT2-02-08: A phase 2 randomized, double-blind, placebo-controlled study of ribociclib or placebo in combination with endocrine therapy for the treatment of premenopausal and postmenopausal Chinese women with HR+, HER2−, advanced breast cancer

Show more Ongoing Clinical Trials

Immunotherapy

Abstract OT-13-02: Bracelet-1 (pre0113): A study to assess overall response rate by inducing an inflammatory phenotype in metastatic breast cancer with the oncolytic reovirus pelareorep in combination with anti-PD-L1 avelumab and paclitaxel
Abstract OT-13-09: Translational breast cancer research consortium 044 trial: Randomized phase 2 study of pembrolizumab and carboplatin versus carboplatin alone for chest wall recurrence of breast cancer
Abstract OT-13-05: Dolaf- an international multicenter phase 2 trial of durvalumab (medi4736) plus olaparib plus fulvestrant in metastatic or locally advanced er-positive, her2-negative breast cancer patients selected using criteria that predict sensitivity to olaparib (UCBG308)

Show more Immunotherapy

Main menu

User menu

Search

Abstract OT1-01-04: A phase 2, open-label study of imprime PGG (Imprime), a novel beta glucan, with pembrolizumab (Pembro) in chemotherapy-resistant metastatic triple negative breast cancer (TNBC)

Online Impact

Statistics from Altmetric.com

ARTICLE USAGE

ARTICLE USAGE: February 2018 to February 2021

Cited By

Article Information

Author Information

Citation Manager Formats

Related Articles

Cited By...

More in this TOC Section

Ongoing Clinical Trials

Immunotherapy

Articles

Info for

About Cancer Research